Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem
2018-000690-78Phase 4Completed
- Sponsor
- Bayer
- Start
- Aug 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of gadobutrol and gadoterate meglumine in None (2 arms), sponsored by Bayer. Primary endpoint: Lesion visualization parameters. Started Aug 2018; status: completed.
02
Drugs
gadobutrolgadoterate meglumine
Beyond the preview
Go deeper on 2018-000690-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000690-78.